Steep Hill and Eybna Partner to Commercialize Customized Cannabis Terpene Formulations

“Delta” the First Customized Terpene Formulation Product for Cannabis-Derived Products

November 15, 2017 – Berkeley, CA – Jmîchaeĺe Keller, President and CEO of Steep Hill and Nadav Eyal, Co-founder and CEO of Eybna announced today that Steep Hill and Eybna Technologies Ltd., have partnered on the first technology to produce custom terpene formulations for incorporation into cannabis-derived products.

Steep Hill is the global leader in cannabis science, testing and analytics. Eybna is a global leader in the research and development of terpene based solutions, with the mission of bringing a native product experience to users of extracted and processed cannabis products by addition of terpenes. Eybna has developed an extension to their core product line, called Delta. Delta is a customized terpene formulation service that enables brands and manufacturers to customize and augment the terpene experience to realize a best-use profile for their customers. The partnership will enable Steep Hill’s expertise in analytical testing for cannabis and cannabis-derived products to customize Eybna’s production of terpene formulations for optimizing the medical benefits of cannabis. Initially, Delta will be available in California, Washington, New Mexico, Alaska, Hawaii and Maryland, with numerous states and countries coming on-line in 2018.

Using analysis from Steep Hill, Eybna will design a customized terpene formulation to assemble the exact materials lost within the process of cannabis extraction using terpenes from natural, non-cannabis origins. This formulation will be tailor-made to provide an optimal terpene mixture in the final product in order to approximate a ‘whole plant’ consumer experience.

Co-founder and CEO of Eybna, Nadav Eyal

As core to our company’s mission, we are already seeing very positive results in our terpene product lines and as we release the Delta product, together we have the potential of changing the lives of millions of consumers worldwide.

“Jmîchaeĺe Keller of Steep Hill said, “The significance of this partnership is enormous for medical patients and cannabis consumers around the globe. For those of us who have worked tirelessly for safety and accuracy in the cannabis market, this product will offer consumers safe, tested, and customized terpene mixtures to return processed cannabis products more closely to the native plant. Some estimates place the number of terpenoids in cannabis at greater than 400, with specific terpenes such as Myrcene, Caryophyllene, Pinene having well documented medicinal benefits. This is a transforming moment for both companies and fits our mission to expand access of this powerful plant to those who need it for their health around the globe.”

ABOUT STEEP HILL

Steep Hill is the world’s leading cannabis science and technology company with significant footprints in lab testing, research and development, licensing, genetics and remote testing. No other company brings all of these sectors into one highly synergistic whole. Steep Hill’s foundation was built on testing and analyzing medical and recreational marijuana to ensure compliance with public safety standards. In 2008, Steep Hill opened the first commercial cannabis lab in the United States and has been on the cutting edge since its inception. Steep Hill is currently expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. Steep Hill: “Leading the Science of Cannabis. Globally.”

For more information about Steep Hill visit: www.steephill.com

ABOUT EYBNA

Eybna is a global leader in the research and development of cannabis terpene based solutions, with the mission of bringing the benefits of cannabis to more patients, by isolating the medicinal properties found in different cannabis phenotypes and providing cannabis medicine that is tailored to treat specific medical conditions.

For more information about Eybna visit: www.eybna.com

Original press release

 

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter